Bristol Myer Squibb (BMS)’s Camzyos has emerged as a groundbreaking treatment for obstructive hypertrophic cardiomyopathy (oHCM), a rare disease in which the muscle in the pumping chamber of the heart becomes thickened, an expert said in an interview with Korea Biomedical Review. Until now, the only
Daewoong Pharmaceutical and Medytox are set to compete in the submental fat improvement injectable market, following botulinum toxin (BTX).Medytox said it applied for a new prdoduct license from the Ministry of Food and Drug Safety for NEWV (MT921 in development name), a lipolysis injection with the
PharmaEssentia's Besremi (ropeginterferon alfa-2b), a treatment for polycythemia vera (PV), showcased exceptional therapeutic efficacy, achieving complete hematologic and molecular biologic responses in Korean patients who did not respond to hydroxyurea therapy, a study showed. Professor Lee Sung-eu
HLB, a Kosdaq-listed anticancer drug developer, said that the combination of the targeted therapy rivoceranib and immunotherapy camrelizumab has proved effective not only in hepatocellular carcinoma (HCC) but also in lung cancer in a phase 2 clinical trial.HLB reported that Jiangsu Hengrui Pharmaceu
Gemvax & Kael, a Kosdaq-listed peptide drug specialist, said on Tuesday that it has submitted a phase 2 investigational new drug (IND) application to the U.S. FDA for GV1001, targeting the treatment of progressive supranuclear palsy (PSP).PSP is an atypical Parkinson's syndrome characterized by rapi
Patients with severe hemophilia A often have to give up even light physical activities due to joint pain, let alone exercise.However, a recent study has shown that these patients drastically improved their quality of life by reducing the frequency of bleeding and could engage in physical activities
Celltrion said Monday that it has received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for a phase 1 Investigational New Drug (IND) application for CT-P55, a Cosentyx (secukinumab) biosimilar for the treatment of psoriasis.Developed by Novartis, Cosentyx is an interl
C&C Research Labs, a subsidiary of JW Pharmaceutical, and XtalPi, a U.S.-based artificial intelligence drug development company, said they will cooperate in developing small molecule therapeutics, focusing on targeting the STAT6 protein, a key player in inflammatory immune responses.XtalPi, founded
For decades, platinum-based chemotherapy has been the gold standard for treating locally advanced or metastatic urothelial cancer. However, the advent of antibody-drug conjugates (ADCs) has changed the treatment of urothelial cancer.In addition to providing a new option as a last resort to urothelia
The Ministry of Food and Drug Safety (MFDS) has imposed administrative penalties for pharmaceutical companies that violated GMP (good manufacturing practice) rules.According to the ministry, CMIC CMO Korea received a 15-day administrative penalty on Dec. 5 to suspend the manufacturing of its ointmen
GC Biopharma’s hematologic treatment is entering the United States, the world’s largest market, for the first time as a Korean product.GC Biopharma said Monday that the company received marketing approval for its intravenous immunodeficiency treatment, Alyglo, from the U.S. Food and Drug Administrat
Kainos Medicine's stock price on Kosdaq shot up by the upper daily limit of 30 percent and closed at 4,615 won ($3.56) on Friday, following the announcement that its two drugs -- Ainuovirine and Ainuomiti -- won national health insurance coverage in China.Ainuovirine and Ainuomiti contain KM-023, an
The Ministry of Food and Drug Safety said Thursday that it has authorized the sale of MSD Korea's Tukysa Tab (50 mg and 150 mg), a new HER2-positive metastatic breast cancer drug.Tukysa is a tyrosine kinase inhibitor (TKI) that selectively inhibits the HER2 receptor overexpressed by cancer cells. It
Celltrion, a Korean biotech firm specializing in biosimilars, said it confirmed the safety and efficacy of CT-P47, a biosimilar referencing Roche’s rheumatoid arthritis drug Actemra (tocilizumab), in a global phase 3 study.The phase 3 study, comparing CT-P47 with Actemra, involved 471 patients with
Hyundai Pharm said Thursday that it launched a U.S. Amazon brand store for its hair loss care brand, Minoxell, and functional cosmetics brand, Labcle, marking its entry into the U.S. beauty business following its entry into China.With the launch of the U.S. Amazon store, Hyundai Pharm will introduce
SK plasma said Thursday that it has shipped the first batch of blood products (albumin and immunoglobulin) to Singapore, initiating its global contract manufacturing organization (CMO) business. The shipment follows SK plasma's selection as the contract manufacturer from the Health Sciences Authorit
“A patient unresponsive to potent medications such as tumor necrosis factor-alpha inhibitors (TNF-α inhibitors) or interleukin-17A (IL-17A) experienced noteworthy pain relief within a mere week of taking Rinvoq (upadacitinib). This rapid response outpaces the typical two-week timeframe associated wi
AstraZeneca Korea announced on Monday its decision to halt the distribution of Forxiga (dapagliflozin) monotherapy, a sodium-glucose transport protein 2 (SGLT-2) diabetes drug, in Korea, effective from the first half of 2024.The company stated that a more detailed schedule for the supply suspension
The Korea Drug Development Fund (KDDF) has selected 10 outstanding examples of new drug development over the past three years, including those carried out by Daewoong Pharmaceutical and CellBion.On Tuesday, the KDDF held the “Presentation of Outstanding National New Drug Development Projects for 202
Celltrion Healthcare said on Tuesday that Vegzelma (bevacizumab), a biosimilar to Genentech’s Avastin for treating metastatic colorectal and breast cancer, is now a preferred drug on Ventegra's U.S. formulary.Ventegra, a leading Pharmacy Benefit Manager (PBM) in the U.S., oversees reimbursement for